Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07691333
What this trial is testing

Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Breast CancerBreast Neoplasms
Fujian Cancer Hospital 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05826964
What this trial is testing

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Who this might be right for
Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more
University of Miami 24
Testing effectiveness (Phase 2)Study completedNCT00015938
What this trial is testing

S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 95
Testing effectiveness (Phase 2)Study completedNCT00629616
What this trial is testing

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 116
Testing effectiveness (Phase 2)Study completedNCT01827787
What this trial is testing

Eribulin in HER2 Negative Metastatic BrCa

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 83
Early research (Phase 1)Study completedNCT03207529
What this trial is testing

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+15 more
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT02723877
What this trial is testing

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Who this might be right for
Metastatic Breast Cancer
PIQUR Therapeutics AG 41
Testing effectiveness (Phase 2)Study completedNCT02260531
What this trial is testing

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Who this might be right for
Breast CancerBrain Tumor - Metastatic
Dana-Farber Cancer Institute 36
Testing effectiveness (Phase 2)UnknownNCT06308939
What this trial is testing

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 81
Not applicableLooking for participantsNCT06902545
What this trial is testing

Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Korea, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT04251169
What this trial is testing

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 20
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Early research (Phase 1)Study completedNCT01624441
What this trial is testing

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05519670
What this trial is testing

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 72
Large-scale testing (Phase 3)Active Not RecruitingNCT04565054
What this trial is testing

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Who this might be right for
Breast Cancer Female
Women's Cancer Study Group GmbH 1,260
Not applicableNot Yet RecruitingNCT07480694
What this trial is testing

Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC

Who this might be right for
Treatment Efficacy
Fudan University 400
Testing effectiveness (Phase 2)Ended earlyNCT02753595
What this trial is testing

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Eisai Inc. 25
Testing effectiveness (Phase 2)UnknownNCT03204734
What this trial is testing

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 132
Testing effectiveness (Phase 2)Looking for participantsNCT07405801
What this trial is testing

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07423611
What this trial is testing

CtDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 388
Next Page
377